RecruitingPhase 4NCT07268313

Complete Remission After Treatment With Biologics for Nasal Polyps

English Title: Complete Remission Study Subtitle: Discontinuation of Mepolizumab or Dupilumab After at Least 12 Months Without Symptoms in Patients With Severe Chronic Rhinosinusitis With Polyps - a National Danish RCT Study


Sponsor

Rigshospitalet, Denmark

Enrollment

66 participants

Start Date

Apr 3, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

In this RCT the investigators randomize patients who are treated with biologic treatment (Nucala or Dupixent) due to nasal polyps and have controlled disease within the last year to either stop treatment og continue as a control group.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DUPIXENT®, Dupi discontinuation, and others for people with nasal polyps. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDUPIXENT®

Continue Dupixent

DRUGNUCALA®

"Continue Nucala

OTHERDupi discontinuation

Stop taking Dupixent at baseline; no substitute is given

OTHERMepo discontinuation

Stop taking Nucala at baseline; no substitute is given


Locations(6)

Rigshospitalet

Copenhagen, Region H, Denmark

Nordsjællands hospital

Hillerød, Region H, Denmark

Køge øre næse hals afd

Køge, Region Sj, Denmark

Dept. of otorhinolaryngology, Odense

Odense, Region Syd, Denmark

Vejle sygehus

Vejle, Region S, Denmark

Gødstrup Hospital

Gødstrup, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07268313


Related Trials